Novavax’s protein-based vaccine approval fails to boost stock as demand for shots and boosters remains low

U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines based on mRNA technology, but the move comes at a time when uptake of shots and boosters is low.